Correction of chronic prostatitis by extracorporeal shock wave therapy
Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT).The study objective was to evaluate the effectiveness of ESWT in the treatment of CP.Materials and methods. The research included...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
M. V. Epifanova [verfasserIn] А. А. Kostin [verfasserIn] E. V. Gameeva [verfasserIn] S. A. Artemenko [verfasserIn] А. А. Epifanov [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Андрология и генитальная хирургия - ABV-press, 2015, 23(2022), 1, Seite 53-59 |
|---|---|
| Übergeordnetes Werk: |
volume:23 ; year:2022 ; number:1 ; pages:53-59 |
| Links: |
|---|
| DOI / URN: |
10.17650/1726-9784-2022-23-1-53-59 |
|---|
| Katalog-ID: |
DOAJ084293039 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ084293039 | ||
| 003 | DE-627 | ||
| 005 | 20230410104953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230311s2022 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17650/1726-9784-2022-23-1-53-59 |2 doi | |
| 035 | |a (DE-627)DOAJ084293039 | ||
| 035 | |a (DE-599)DOAJ54213f73dc9548f5bc6c53e0ba250ed6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RD1-811 | |
| 050 | 0 | |a RC870-923 | |
| 100 | 0 | |a M. V. Epifanova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Correction of chronic prostatitis by extracorporeal shock wave therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT).The study objective was to evaluate the effectiveness of ESWT in the treatment of CP.Materials and methods. The research included 43 patients with CP. The patient’s age was 38.8 (27–65). The mean CP duration was 13.5 (3–24) months. 43 patients were assigned into 3 groups based on transrectal ultrasound (TRUS) examination. Group 1 had fibrotic changes in the prostate (n = 21). Group 2 had prostate calcifications (n = 5). Group 3 had fibrotic changes and calcifications in the prostate (n = 17). Treatment included ESWT (Dornier Aries) twice per week during 6 weeks. Each ESWT-session was comprised 2000–3500 pulses (0.05–0.062 mJ/mm2) and 8–6 Hz of frequency. All men were evaluated on 0 and 60 days of the study using NIH-CPSI (National Institutes Health Chronic Prostatitis Symptom Index), IPSS (International Prostate Symptom Score), TRUS of the prostate, the culture of seminal or prostate fluid, spermogram or prostate fluid analysis, serum prostatic specific antigen for men over 50 years of age.Results. The patients over 50 years-old had total prostatic specific antigen less than 4 ng/ml. Bacterial growth was found in the culture of seminal/prostate fluid of the 26 patients. They were additionally prescribed antibiotics according to antibiogram. All patients got the treatment well. Control study pointed at lower scores of NIH-CPSI – grade decreased from 13.39 (1–34) to 5.54 (0–24) (p <0.05), IPSS decreased from 11.39 (0–34) to 4.39 (0–29) (p <0.05). Prostate volume decreased from 25.18 (12.2–58.8) cm3 to 22.78 (12–56.6) cm3 according to TRUS (p >0.05). In the group 1 in 3 cases local fibrosis were completely resolved, in 18 cases fibrotic changes decreased from 5.3 (0–13) mm to 3.24 (0–8.1) mm (p <0.05). In the second group the number and the size of calcifications decreased from 6.92 (2–21) mm to 4 (0–20) mm (p >0.05). In the group 3 calcifications were completely resolved (p <0.05), the volume of fibrosis decreased from 6.8 (3.2–15) mm to 4.5 (1–17) mm (p <0.05). Bacterial growth wasn’t found in 9 patients’ seminal/ prostate fluid, 16 patients had a decrease of the causative agent concentration on 60 day, WBC count normalized in all subjects with CP/chronic pelvic pain syndrome IIIA.Conclusion. ESWT is an effective and non-invasive method of treatment of CP type II, IIIA and IIIB. The proposed treatment to relieve pain syndrome, inflammation, to promote lysis of fibrosis zone and calcinates, improves the draining function of prostate, contributing to accelerated elimination of microflora. | ||
| 650 | 4 | |a chronic prostatitis | |
| 650 | 4 | |a extracorporeal shock wave therapy | |
| 650 | 4 | |a chronic pelvic pain syndrome | |
| 650 | 4 | |a prostate | |
| 650 | 4 | |a inflammation | |
| 653 | 0 | |a Surgery | |
| 653 | 0 | |a Diseases of the genitourinary system. Urology | |
| 700 | 0 | |a А. А. Kostin |e verfasserin |4 aut | |
| 700 | 0 | |a E. V. Gameeva |e verfasserin |4 aut | |
| 700 | 0 | |a S. A. Artemenko |e verfasserin |4 aut | |
| 700 | 0 | |a А. А. Epifanov |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Андрология и генитальная хирургия |d ABV-press, 2015 |g 23(2022), 1, Seite 53-59 |w (DE-627)1760599980 |x 20709781 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:1 |g pages:53-59 |
| 856 | 4 | 0 | |u https://doi.org/10.17650/1726-9784-2022-23-1-53-59 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/54213f73dc9548f5bc6c53e0ba250ed6 |z kostenfrei |
| 856 | 4 | 0 | |u https://agx.abvpress.ru/jour/article/view/545 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2070-9781 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 1 |h 53-59 | ||
| author_variant |
m v e mve а а k ааk e v g evg s a a saa а а e ааe |
|---|---|
| matchkey_str |
article:20709781:2022----::orcinfhoipotttsyxrcroe |
| hierarchy_sort_str |
2022 |
| callnumber-subject-code |
RD |
| publishDate |
2022 |
| allfields |
10.17650/1726-9784-2022-23-1-53-59 doi (DE-627)DOAJ084293039 (DE-599)DOAJ54213f73dc9548f5bc6c53e0ba250ed6 DE-627 ger DE-627 rakwb rus RD1-811 RC870-923 M. V. Epifanova verfasserin aut Correction of chronic prostatitis by extracorporeal shock wave therapy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT).The study objective was to evaluate the effectiveness of ESWT in the treatment of CP.Materials and methods. The research included 43 patients with CP. The patient’s age was 38.8 (27–65). The mean CP duration was 13.5 (3–24) months. 43 patients were assigned into 3 groups based on transrectal ultrasound (TRUS) examination. Group 1 had fibrotic changes in the prostate (n = 21). Group 2 had prostate calcifications (n = 5). Group 3 had fibrotic changes and calcifications in the prostate (n = 17). Treatment included ESWT (Dornier Aries) twice per week during 6 weeks. Each ESWT-session was comprised 2000–3500 pulses (0.05–0.062 mJ/mm2) and 8–6 Hz of frequency. All men were evaluated on 0 and 60 days of the study using NIH-CPSI (National Institutes Health Chronic Prostatitis Symptom Index), IPSS (International Prostate Symptom Score), TRUS of the prostate, the culture of seminal or prostate fluid, spermogram or prostate fluid analysis, serum prostatic specific antigen for men over 50 years of age.Results. The patients over 50 years-old had total prostatic specific antigen less than 4 ng/ml. Bacterial growth was found in the culture of seminal/prostate fluid of the 26 patients. They were additionally prescribed antibiotics according to antibiogram. All patients got the treatment well. Control study pointed at lower scores of NIH-CPSI – grade decreased from 13.39 (1–34) to 5.54 (0–24) (p <0.05), IPSS decreased from 11.39 (0–34) to 4.39 (0–29) (p <0.05). Prostate volume decreased from 25.18 (12.2–58.8) cm3 to 22.78 (12–56.6) cm3 according to TRUS (p >0.05). In the group 1 in 3 cases local fibrosis were completely resolved, in 18 cases fibrotic changes decreased from 5.3 (0–13) mm to 3.24 (0–8.1) mm (p <0.05). In the second group the number and the size of calcifications decreased from 6.92 (2–21) mm to 4 (0–20) mm (p >0.05). In the group 3 calcifications were completely resolved (p <0.05), the volume of fibrosis decreased from 6.8 (3.2–15) mm to 4.5 (1–17) mm (p <0.05). Bacterial growth wasn’t found in 9 patients’ seminal/ prostate fluid, 16 patients had a decrease of the causative agent concentration on 60 day, WBC count normalized in all subjects with CP/chronic pelvic pain syndrome IIIA.Conclusion. ESWT is an effective and non-invasive method of treatment of CP type II, IIIA and IIIB. The proposed treatment to relieve pain syndrome, inflammation, to promote lysis of fibrosis zone and calcinates, improves the draining function of prostate, contributing to accelerated elimination of microflora. chronic prostatitis extracorporeal shock wave therapy chronic pelvic pain syndrome prostate inflammation Surgery Diseases of the genitourinary system. Urology А. А. Kostin verfasserin aut E. V. Gameeva verfasserin aut S. A. Artemenko verfasserin aut А. А. Epifanov verfasserin aut In Андрология и генитальная хирургия ABV-press, 2015 23(2022), 1, Seite 53-59 (DE-627)1760599980 20709781 nnns volume:23 year:2022 number:1 pages:53-59 https://doi.org/10.17650/1726-9784-2022-23-1-53-59 kostenfrei https://doaj.org/article/54213f73dc9548f5bc6c53e0ba250ed6 kostenfrei https://agx.abvpress.ru/jour/article/view/545 kostenfrei https://doaj.org/toc/2070-9781 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 23 2022 1 53-59 |
| spelling |
10.17650/1726-9784-2022-23-1-53-59 doi (DE-627)DOAJ084293039 (DE-599)DOAJ54213f73dc9548f5bc6c53e0ba250ed6 DE-627 ger DE-627 rakwb rus RD1-811 RC870-923 M. V. Epifanova verfasserin aut Correction of chronic prostatitis by extracorporeal shock wave therapy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT).The study objective was to evaluate the effectiveness of ESWT in the treatment of CP.Materials and methods. The research included 43 patients with CP. The patient’s age was 38.8 (27–65). The mean CP duration was 13.5 (3–24) months. 43 patients were assigned into 3 groups based on transrectal ultrasound (TRUS) examination. Group 1 had fibrotic changes in the prostate (n = 21). Group 2 had prostate calcifications (n = 5). Group 3 had fibrotic changes and calcifications in the prostate (n = 17). Treatment included ESWT (Dornier Aries) twice per week during 6 weeks. Each ESWT-session was comprised 2000–3500 pulses (0.05–0.062 mJ/mm2) and 8–6 Hz of frequency. All men were evaluated on 0 and 60 days of the study using NIH-CPSI (National Institutes Health Chronic Prostatitis Symptom Index), IPSS (International Prostate Symptom Score), TRUS of the prostate, the culture of seminal or prostate fluid, spermogram or prostate fluid analysis, serum prostatic specific antigen for men over 50 years of age.Results. The patients over 50 years-old had total prostatic specific antigen less than 4 ng/ml. Bacterial growth was found in the culture of seminal/prostate fluid of the 26 patients. They were additionally prescribed antibiotics according to antibiogram. All patients got the treatment well. Control study pointed at lower scores of NIH-CPSI – grade decreased from 13.39 (1–34) to 5.54 (0–24) (p <0.05), IPSS decreased from 11.39 (0–34) to 4.39 (0–29) (p <0.05). Prostate volume decreased from 25.18 (12.2–58.8) cm3 to 22.78 (12–56.6) cm3 according to TRUS (p >0.05). In the group 1 in 3 cases local fibrosis were completely resolved, in 18 cases fibrotic changes decreased from 5.3 (0–13) mm to 3.24 (0–8.1) mm (p <0.05). In the second group the number and the size of calcifications decreased from 6.92 (2–21) mm to 4 (0–20) mm (p >0.05). In the group 3 calcifications were completely resolved (p <0.05), the volume of fibrosis decreased from 6.8 (3.2–15) mm to 4.5 (1–17) mm (p <0.05). Bacterial growth wasn’t found in 9 patients’ seminal/ prostate fluid, 16 patients had a decrease of the causative agent concentration on 60 day, WBC count normalized in all subjects with CP/chronic pelvic pain syndrome IIIA.Conclusion. ESWT is an effective and non-invasive method of treatment of CP type II, IIIA and IIIB. The proposed treatment to relieve pain syndrome, inflammation, to promote lysis of fibrosis zone and calcinates, improves the draining function of prostate, contributing to accelerated elimination of microflora. chronic prostatitis extracorporeal shock wave therapy chronic pelvic pain syndrome prostate inflammation Surgery Diseases of the genitourinary system. Urology А. А. Kostin verfasserin aut E. V. Gameeva verfasserin aut S. A. Artemenko verfasserin aut А. А. Epifanov verfasserin aut In Андрология и генитальная хирургия ABV-press, 2015 23(2022), 1, Seite 53-59 (DE-627)1760599980 20709781 nnns volume:23 year:2022 number:1 pages:53-59 https://doi.org/10.17650/1726-9784-2022-23-1-53-59 kostenfrei https://doaj.org/article/54213f73dc9548f5bc6c53e0ba250ed6 kostenfrei https://agx.abvpress.ru/jour/article/view/545 kostenfrei https://doaj.org/toc/2070-9781 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 23 2022 1 53-59 |
| allfields_unstemmed |
10.17650/1726-9784-2022-23-1-53-59 doi (DE-627)DOAJ084293039 (DE-599)DOAJ54213f73dc9548f5bc6c53e0ba250ed6 DE-627 ger DE-627 rakwb rus RD1-811 RC870-923 M. V. Epifanova verfasserin aut Correction of chronic prostatitis by extracorporeal shock wave therapy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT).The study objective was to evaluate the effectiveness of ESWT in the treatment of CP.Materials and methods. The research included 43 patients with CP. The patient’s age was 38.8 (27–65). The mean CP duration was 13.5 (3–24) months. 43 patients were assigned into 3 groups based on transrectal ultrasound (TRUS) examination. Group 1 had fibrotic changes in the prostate (n = 21). Group 2 had prostate calcifications (n = 5). Group 3 had fibrotic changes and calcifications in the prostate (n = 17). Treatment included ESWT (Dornier Aries) twice per week during 6 weeks. Each ESWT-session was comprised 2000–3500 pulses (0.05–0.062 mJ/mm2) and 8–6 Hz of frequency. All men were evaluated on 0 and 60 days of the study using NIH-CPSI (National Institutes Health Chronic Prostatitis Symptom Index), IPSS (International Prostate Symptom Score), TRUS of the prostate, the culture of seminal or prostate fluid, spermogram or prostate fluid analysis, serum prostatic specific antigen for men over 50 years of age.Results. The patients over 50 years-old had total prostatic specific antigen less than 4 ng/ml. Bacterial growth was found in the culture of seminal/prostate fluid of the 26 patients. They were additionally prescribed antibiotics according to antibiogram. All patients got the treatment well. Control study pointed at lower scores of NIH-CPSI – grade decreased from 13.39 (1–34) to 5.54 (0–24) (p <0.05), IPSS decreased from 11.39 (0–34) to 4.39 (0–29) (p <0.05). Prostate volume decreased from 25.18 (12.2–58.8) cm3 to 22.78 (12–56.6) cm3 according to TRUS (p >0.05). In the group 1 in 3 cases local fibrosis were completely resolved, in 18 cases fibrotic changes decreased from 5.3 (0–13) mm to 3.24 (0–8.1) mm (p <0.05). In the second group the number and the size of calcifications decreased from 6.92 (2–21) mm to 4 (0–20) mm (p >0.05). In the group 3 calcifications were completely resolved (p <0.05), the volume of fibrosis decreased from 6.8 (3.2–15) mm to 4.5 (1–17) mm (p <0.05). Bacterial growth wasn’t found in 9 patients’ seminal/ prostate fluid, 16 patients had a decrease of the causative agent concentration on 60 day, WBC count normalized in all subjects with CP/chronic pelvic pain syndrome IIIA.Conclusion. ESWT is an effective and non-invasive method of treatment of CP type II, IIIA and IIIB. The proposed treatment to relieve pain syndrome, inflammation, to promote lysis of fibrosis zone and calcinates, improves the draining function of prostate, contributing to accelerated elimination of microflora. chronic prostatitis extracorporeal shock wave therapy chronic pelvic pain syndrome prostate inflammation Surgery Diseases of the genitourinary system. Urology А. А. Kostin verfasserin aut E. V. Gameeva verfasserin aut S. A. Artemenko verfasserin aut А. А. Epifanov verfasserin aut In Андрология и генитальная хирургия ABV-press, 2015 23(2022), 1, Seite 53-59 (DE-627)1760599980 20709781 nnns volume:23 year:2022 number:1 pages:53-59 https://doi.org/10.17650/1726-9784-2022-23-1-53-59 kostenfrei https://doaj.org/article/54213f73dc9548f5bc6c53e0ba250ed6 kostenfrei https://agx.abvpress.ru/jour/article/view/545 kostenfrei https://doaj.org/toc/2070-9781 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 23 2022 1 53-59 |
| allfieldsGer |
10.17650/1726-9784-2022-23-1-53-59 doi (DE-627)DOAJ084293039 (DE-599)DOAJ54213f73dc9548f5bc6c53e0ba250ed6 DE-627 ger DE-627 rakwb rus RD1-811 RC870-923 M. V. Epifanova verfasserin aut Correction of chronic prostatitis by extracorporeal shock wave therapy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT).The study objective was to evaluate the effectiveness of ESWT in the treatment of CP.Materials and methods. The research included 43 patients with CP. The patient’s age was 38.8 (27–65). The mean CP duration was 13.5 (3–24) months. 43 patients were assigned into 3 groups based on transrectal ultrasound (TRUS) examination. Group 1 had fibrotic changes in the prostate (n = 21). Group 2 had prostate calcifications (n = 5). Group 3 had fibrotic changes and calcifications in the prostate (n = 17). Treatment included ESWT (Dornier Aries) twice per week during 6 weeks. Each ESWT-session was comprised 2000–3500 pulses (0.05–0.062 mJ/mm2) and 8–6 Hz of frequency. All men were evaluated on 0 and 60 days of the study using NIH-CPSI (National Institutes Health Chronic Prostatitis Symptom Index), IPSS (International Prostate Symptom Score), TRUS of the prostate, the culture of seminal or prostate fluid, spermogram or prostate fluid analysis, serum prostatic specific antigen for men over 50 years of age.Results. The patients over 50 years-old had total prostatic specific antigen less than 4 ng/ml. Bacterial growth was found in the culture of seminal/prostate fluid of the 26 patients. They were additionally prescribed antibiotics according to antibiogram. All patients got the treatment well. Control study pointed at lower scores of NIH-CPSI – grade decreased from 13.39 (1–34) to 5.54 (0–24) (p <0.05), IPSS decreased from 11.39 (0–34) to 4.39 (0–29) (p <0.05). Prostate volume decreased from 25.18 (12.2–58.8) cm3 to 22.78 (12–56.6) cm3 according to TRUS (p >0.05). In the group 1 in 3 cases local fibrosis were completely resolved, in 18 cases fibrotic changes decreased from 5.3 (0–13) mm to 3.24 (0–8.1) mm (p <0.05). In the second group the number and the size of calcifications decreased from 6.92 (2–21) mm to 4 (0–20) mm (p >0.05). In the group 3 calcifications were completely resolved (p <0.05), the volume of fibrosis decreased from 6.8 (3.2–15) mm to 4.5 (1–17) mm (p <0.05). Bacterial growth wasn’t found in 9 patients’ seminal/ prostate fluid, 16 patients had a decrease of the causative agent concentration on 60 day, WBC count normalized in all subjects with CP/chronic pelvic pain syndrome IIIA.Conclusion. ESWT is an effective and non-invasive method of treatment of CP type II, IIIA and IIIB. The proposed treatment to relieve pain syndrome, inflammation, to promote lysis of fibrosis zone and calcinates, improves the draining function of prostate, contributing to accelerated elimination of microflora. chronic prostatitis extracorporeal shock wave therapy chronic pelvic pain syndrome prostate inflammation Surgery Diseases of the genitourinary system. Urology А. А. Kostin verfasserin aut E. V. Gameeva verfasserin aut S. A. Artemenko verfasserin aut А. А. Epifanov verfasserin aut In Андрология и генитальная хирургия ABV-press, 2015 23(2022), 1, Seite 53-59 (DE-627)1760599980 20709781 nnns volume:23 year:2022 number:1 pages:53-59 https://doi.org/10.17650/1726-9784-2022-23-1-53-59 kostenfrei https://doaj.org/article/54213f73dc9548f5bc6c53e0ba250ed6 kostenfrei https://agx.abvpress.ru/jour/article/view/545 kostenfrei https://doaj.org/toc/2070-9781 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 23 2022 1 53-59 |
| allfieldsSound |
10.17650/1726-9784-2022-23-1-53-59 doi (DE-627)DOAJ084293039 (DE-599)DOAJ54213f73dc9548f5bc6c53e0ba250ed6 DE-627 ger DE-627 rakwb rus RD1-811 RC870-923 M. V. Epifanova verfasserin aut Correction of chronic prostatitis by extracorporeal shock wave therapy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT).The study objective was to evaluate the effectiveness of ESWT in the treatment of CP.Materials and methods. The research included 43 patients with CP. The patient’s age was 38.8 (27–65). The mean CP duration was 13.5 (3–24) months. 43 patients were assigned into 3 groups based on transrectal ultrasound (TRUS) examination. Group 1 had fibrotic changes in the prostate (n = 21). Group 2 had prostate calcifications (n = 5). Group 3 had fibrotic changes and calcifications in the prostate (n = 17). Treatment included ESWT (Dornier Aries) twice per week during 6 weeks. Each ESWT-session was comprised 2000–3500 pulses (0.05–0.062 mJ/mm2) and 8–6 Hz of frequency. All men were evaluated on 0 and 60 days of the study using NIH-CPSI (National Institutes Health Chronic Prostatitis Symptom Index), IPSS (International Prostate Symptom Score), TRUS of the prostate, the culture of seminal or prostate fluid, spermogram or prostate fluid analysis, serum prostatic specific antigen for men over 50 years of age.Results. The patients over 50 years-old had total prostatic specific antigen less than 4 ng/ml. Bacterial growth was found in the culture of seminal/prostate fluid of the 26 patients. They were additionally prescribed antibiotics according to antibiogram. All patients got the treatment well. Control study pointed at lower scores of NIH-CPSI – grade decreased from 13.39 (1–34) to 5.54 (0–24) (p <0.05), IPSS decreased from 11.39 (0–34) to 4.39 (0–29) (p <0.05). Prostate volume decreased from 25.18 (12.2–58.8) cm3 to 22.78 (12–56.6) cm3 according to TRUS (p >0.05). In the group 1 in 3 cases local fibrosis were completely resolved, in 18 cases fibrotic changes decreased from 5.3 (0–13) mm to 3.24 (0–8.1) mm (p <0.05). In the second group the number and the size of calcifications decreased from 6.92 (2–21) mm to 4 (0–20) mm (p >0.05). In the group 3 calcifications were completely resolved (p <0.05), the volume of fibrosis decreased from 6.8 (3.2–15) mm to 4.5 (1–17) mm (p <0.05). Bacterial growth wasn’t found in 9 patients’ seminal/ prostate fluid, 16 patients had a decrease of the causative agent concentration on 60 day, WBC count normalized in all subjects with CP/chronic pelvic pain syndrome IIIA.Conclusion. ESWT is an effective and non-invasive method of treatment of CP type II, IIIA and IIIB. The proposed treatment to relieve pain syndrome, inflammation, to promote lysis of fibrosis zone and calcinates, improves the draining function of prostate, contributing to accelerated elimination of microflora. chronic prostatitis extracorporeal shock wave therapy chronic pelvic pain syndrome prostate inflammation Surgery Diseases of the genitourinary system. Urology А. А. Kostin verfasserin aut E. V. Gameeva verfasserin aut S. A. Artemenko verfasserin aut А. А. Epifanov verfasserin aut In Андрология и генитальная хирургия ABV-press, 2015 23(2022), 1, Seite 53-59 (DE-627)1760599980 20709781 nnns volume:23 year:2022 number:1 pages:53-59 https://doi.org/10.17650/1726-9784-2022-23-1-53-59 kostenfrei https://doaj.org/article/54213f73dc9548f5bc6c53e0ba250ed6 kostenfrei https://agx.abvpress.ru/jour/article/view/545 kostenfrei https://doaj.org/toc/2070-9781 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 23 2022 1 53-59 |
| language |
Russian |
| source |
In Андрология и генитальная хирургия 23(2022), 1, Seite 53-59 volume:23 year:2022 number:1 pages:53-59 |
| sourceStr |
In Андрология и генитальная хирургия 23(2022), 1, Seite 53-59 volume:23 year:2022 number:1 pages:53-59 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
chronic prostatitis extracorporeal shock wave therapy chronic pelvic pain syndrome prostate inflammation Surgery Diseases of the genitourinary system. Urology |
| isfreeaccess_bool |
true |
| container_title |
Андрология и генитальная хирургия |
| authorswithroles_txt_mv |
M. V. Epifanova @@aut@@ А. А. Kostin @@aut@@ E. V. Gameeva @@aut@@ S. A. Artemenko @@aut@@ А. А. Epifanov @@aut@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
1760599980 |
| id |
DOAJ084293039 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ084293039</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410104953.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2022 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17650/1726-9784-2022-23-1-53-59</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ084293039</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ54213f73dc9548f5bc6c53e0ba250ed6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RD1-811</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">M. V. Epifanova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Correction of chronic prostatitis by extracorporeal shock wave therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT).The study objective was to evaluate the effectiveness of ESWT in the treatment of CP.Materials and methods. The research included 43 patients with CP. The patient’s age was 38.8 (27–65). The mean CP duration was 13.5 (3–24) months. 43 patients were assigned into 3 groups based on transrectal ultrasound (TRUS) examination. Group 1 had fibrotic changes in the prostate (n = 21). Group 2 had prostate calcifications (n = 5). Group 3 had fibrotic changes and calcifications in the prostate (n = 17). Treatment included ESWT (Dornier Aries) twice per week during 6 weeks. Each ESWT-session was comprised 2000–3500 pulses (0.05–0.062 mJ/mm2) and 8–6 Hz of frequency. All men were evaluated on 0 and 60 days of the study using NIH-CPSI (National Institutes Health Chronic Prostatitis Symptom Index), IPSS (International Prostate Symptom Score), TRUS of the prostate, the culture of seminal or prostate fluid, spermogram or prostate fluid analysis, serum prostatic specific antigen for men over 50 years of age.Results. The patients over 50 years-old had total prostatic specific antigen less than 4 ng/ml. Bacterial growth was found in the culture of seminal/prostate fluid of the 26 patients. They were additionally prescribed antibiotics according to antibiogram. All patients got the treatment well. Control study pointed at lower scores of NIH-CPSI – grade decreased from 13.39 (1–34) to 5.54 (0–24) (p &lt;0.05), IPSS decreased from 11.39 (0–34) to 4.39 (0–29) (p &lt;0.05). Prostate volume decreased from 25.18 (12.2–58.8) cm3 to 22.78 (12–56.6) cm3 according to TRUS (p &gt;0.05). In the group 1 in 3 cases local fibrosis were completely resolved, in 18 cases fibrotic changes decreased from 5.3 (0–13) mm to 3.24 (0–8.1) mm (p &lt;0.05). In the second group the number and the size of calcifications decreased from 6.92 (2–21) mm to 4 (0–20) mm (p &gt;0.05). In the group 3 calcifications were completely resolved (p &lt;0.05), the volume of fibrosis decreased from 6.8 (3.2–15) mm to 4.5 (1–17) mm (p &lt;0.05). Bacterial growth wasn’t found in 9 patients’ seminal/ prostate fluid, 16 patients had a decrease of the causative agent concentration on 60 day, WBC count normalized in all subjects with CP/chronic pelvic pain syndrome IIIA.Conclusion. ESWT is an effective and non-invasive method of treatment of CP type II, IIIA and IIIB. The proposed treatment to relieve pain syndrome, inflammation, to promote lysis of fibrosis zone and calcinates, improves the draining function of prostate, contributing to accelerated elimination of microflora.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic prostatitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">extracorporeal shock wave therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic pelvic pain syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Surgery</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">А. А. Kostin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Gameeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. A. Artemenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">А. А. Epifanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Андрология и генитальная хирургия</subfield><subfield code="d">ABV-press, 2015</subfield><subfield code="g">23(2022), 1, Seite 53-59</subfield><subfield code="w">(DE-627)1760599980</subfield><subfield code="x">20709781</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:53-59</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17650/1726-9784-2022-23-1-53-59</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/54213f73dc9548f5bc6c53e0ba250ed6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://agx.abvpress.ru/jour/article/view/545</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-9781</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">53-59</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
M. V. Epifanova |
| spellingShingle |
M. V. Epifanova misc RD1-811 misc RC870-923 misc chronic prostatitis misc extracorporeal shock wave therapy misc chronic pelvic pain syndrome misc prostate misc inflammation misc Surgery misc Diseases of the genitourinary system. Urology Correction of chronic prostatitis by extracorporeal shock wave therapy |
| authorStr |
M. V. Epifanova |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760599980 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RD1-811 |
| illustrated |
Not Illustrated |
| issn |
20709781 |
| topic_title |
RD1-811 RC870-923 Correction of chronic prostatitis by extracorporeal shock wave therapy chronic prostatitis extracorporeal shock wave therapy chronic pelvic pain syndrome prostate inflammation |
| topic |
misc RD1-811 misc RC870-923 misc chronic prostatitis misc extracorporeal shock wave therapy misc chronic pelvic pain syndrome misc prostate misc inflammation misc Surgery misc Diseases of the genitourinary system. Urology |
| topic_unstemmed |
misc RD1-811 misc RC870-923 misc chronic prostatitis misc extracorporeal shock wave therapy misc chronic pelvic pain syndrome misc prostate misc inflammation misc Surgery misc Diseases of the genitourinary system. Urology |
| topic_browse |
misc RD1-811 misc RC870-923 misc chronic prostatitis misc extracorporeal shock wave therapy misc chronic pelvic pain syndrome misc prostate misc inflammation misc Surgery misc Diseases of the genitourinary system. Urology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Андрология и генитальная хирургия |
| hierarchy_parent_id |
1760599980 |
| hierarchy_top_title |
Андрология и генитальная хирургия |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760599980 |
| title |
Correction of chronic prostatitis by extracorporeal shock wave therapy |
| ctrlnum |
(DE-627)DOAJ084293039 (DE-599)DOAJ54213f73dc9548f5bc6c53e0ba250ed6 |
| title_full |
Correction of chronic prostatitis by extracorporeal shock wave therapy |
| author_sort |
M. V. Epifanova |
| journal |
Андрология и генитальная хирургия |
| journalStr |
Андрология и генитальная хирургия |
| callnumber-first-code |
R |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| container_start_page |
53 |
| author_browse |
M. V. Epifanova А. А. Kostin E. V. Gameeva S. A. Artemenko А. А. Epifanov |
| container_volume |
23 |
| class |
RD1-811 RC870-923 |
| format_se |
Elektronische Aufsätze |
| author-letter |
M. V. Epifanova |
| doi_str_mv |
10.17650/1726-9784-2022-23-1-53-59 |
| author2-role |
verfasserin |
| title_sort |
correction of chronic prostatitis by extracorporeal shock wave therapy |
| callnumber |
RD1-811 |
| title_auth |
Correction of chronic prostatitis by extracorporeal shock wave therapy |
| abstract |
Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT).The study objective was to evaluate the effectiveness of ESWT in the treatment of CP.Materials and methods. The research included 43 patients with CP. The patient’s age was 38.8 (27–65). The mean CP duration was 13.5 (3–24) months. 43 patients were assigned into 3 groups based on transrectal ultrasound (TRUS) examination. Group 1 had fibrotic changes in the prostate (n = 21). Group 2 had prostate calcifications (n = 5). Group 3 had fibrotic changes and calcifications in the prostate (n = 17). Treatment included ESWT (Dornier Aries) twice per week during 6 weeks. Each ESWT-session was comprised 2000–3500 pulses (0.05–0.062 mJ/mm2) and 8–6 Hz of frequency. All men were evaluated on 0 and 60 days of the study using NIH-CPSI (National Institutes Health Chronic Prostatitis Symptom Index), IPSS (International Prostate Symptom Score), TRUS of the prostate, the culture of seminal or prostate fluid, spermogram or prostate fluid analysis, serum prostatic specific antigen for men over 50 years of age.Results. The patients over 50 years-old had total prostatic specific antigen less than 4 ng/ml. Bacterial growth was found in the culture of seminal/prostate fluid of the 26 patients. They were additionally prescribed antibiotics according to antibiogram. All patients got the treatment well. Control study pointed at lower scores of NIH-CPSI – grade decreased from 13.39 (1–34) to 5.54 (0–24) (p <0.05), IPSS decreased from 11.39 (0–34) to 4.39 (0–29) (p <0.05). Prostate volume decreased from 25.18 (12.2–58.8) cm3 to 22.78 (12–56.6) cm3 according to TRUS (p >0.05). In the group 1 in 3 cases local fibrosis were completely resolved, in 18 cases fibrotic changes decreased from 5.3 (0–13) mm to 3.24 (0–8.1) mm (p <0.05). In the second group the number and the size of calcifications decreased from 6.92 (2–21) mm to 4 (0–20) mm (p >0.05). In the group 3 calcifications were completely resolved (p <0.05), the volume of fibrosis decreased from 6.8 (3.2–15) mm to 4.5 (1–17) mm (p <0.05). Bacterial growth wasn’t found in 9 patients’ seminal/ prostate fluid, 16 patients had a decrease of the causative agent concentration on 60 day, WBC count normalized in all subjects with CP/chronic pelvic pain syndrome IIIA.Conclusion. ESWT is an effective and non-invasive method of treatment of CP type II, IIIA and IIIB. The proposed treatment to relieve pain syndrome, inflammation, to promote lysis of fibrosis zone and calcinates, improves the draining function of prostate, contributing to accelerated elimination of microflora. |
| abstractGer |
Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT).The study objective was to evaluate the effectiveness of ESWT in the treatment of CP.Materials and methods. The research included 43 patients with CP. The patient’s age was 38.8 (27–65). The mean CP duration was 13.5 (3–24) months. 43 patients were assigned into 3 groups based on transrectal ultrasound (TRUS) examination. Group 1 had fibrotic changes in the prostate (n = 21). Group 2 had prostate calcifications (n = 5). Group 3 had fibrotic changes and calcifications in the prostate (n = 17). Treatment included ESWT (Dornier Aries) twice per week during 6 weeks. Each ESWT-session was comprised 2000–3500 pulses (0.05–0.062 mJ/mm2) and 8–6 Hz of frequency. All men were evaluated on 0 and 60 days of the study using NIH-CPSI (National Institutes Health Chronic Prostatitis Symptom Index), IPSS (International Prostate Symptom Score), TRUS of the prostate, the culture of seminal or prostate fluid, spermogram or prostate fluid analysis, serum prostatic specific antigen for men over 50 years of age.Results. The patients over 50 years-old had total prostatic specific antigen less than 4 ng/ml. Bacterial growth was found in the culture of seminal/prostate fluid of the 26 patients. They were additionally prescribed antibiotics according to antibiogram. All patients got the treatment well. Control study pointed at lower scores of NIH-CPSI – grade decreased from 13.39 (1–34) to 5.54 (0–24) (p <0.05), IPSS decreased from 11.39 (0–34) to 4.39 (0–29) (p <0.05). Prostate volume decreased from 25.18 (12.2–58.8) cm3 to 22.78 (12–56.6) cm3 according to TRUS (p >0.05). In the group 1 in 3 cases local fibrosis were completely resolved, in 18 cases fibrotic changes decreased from 5.3 (0–13) mm to 3.24 (0–8.1) mm (p <0.05). In the second group the number and the size of calcifications decreased from 6.92 (2–21) mm to 4 (0–20) mm (p >0.05). In the group 3 calcifications were completely resolved (p <0.05), the volume of fibrosis decreased from 6.8 (3.2–15) mm to 4.5 (1–17) mm (p <0.05). Bacterial growth wasn’t found in 9 patients’ seminal/ prostate fluid, 16 patients had a decrease of the causative agent concentration on 60 day, WBC count normalized in all subjects with CP/chronic pelvic pain syndrome IIIA.Conclusion. ESWT is an effective and non-invasive method of treatment of CP type II, IIIA and IIIB. The proposed treatment to relieve pain syndrome, inflammation, to promote lysis of fibrosis zone and calcinates, improves the draining function of prostate, contributing to accelerated elimination of microflora. |
| abstract_unstemmed |
Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT).The study objective was to evaluate the effectiveness of ESWT in the treatment of CP.Materials and methods. The research included 43 patients with CP. The patient’s age was 38.8 (27–65). The mean CP duration was 13.5 (3–24) months. 43 patients were assigned into 3 groups based on transrectal ultrasound (TRUS) examination. Group 1 had fibrotic changes in the prostate (n = 21). Group 2 had prostate calcifications (n = 5). Group 3 had fibrotic changes and calcifications in the prostate (n = 17). Treatment included ESWT (Dornier Aries) twice per week during 6 weeks. Each ESWT-session was comprised 2000–3500 pulses (0.05–0.062 mJ/mm2) and 8–6 Hz of frequency. All men were evaluated on 0 and 60 days of the study using NIH-CPSI (National Institutes Health Chronic Prostatitis Symptom Index), IPSS (International Prostate Symptom Score), TRUS of the prostate, the culture of seminal or prostate fluid, spermogram or prostate fluid analysis, serum prostatic specific antigen for men over 50 years of age.Results. The patients over 50 years-old had total prostatic specific antigen less than 4 ng/ml. Bacterial growth was found in the culture of seminal/prostate fluid of the 26 patients. They were additionally prescribed antibiotics according to antibiogram. All patients got the treatment well. Control study pointed at lower scores of NIH-CPSI – grade decreased from 13.39 (1–34) to 5.54 (0–24) (p <0.05), IPSS decreased from 11.39 (0–34) to 4.39 (0–29) (p <0.05). Prostate volume decreased from 25.18 (12.2–58.8) cm3 to 22.78 (12–56.6) cm3 according to TRUS (p >0.05). In the group 1 in 3 cases local fibrosis were completely resolved, in 18 cases fibrotic changes decreased from 5.3 (0–13) mm to 3.24 (0–8.1) mm (p <0.05). In the second group the number and the size of calcifications decreased from 6.92 (2–21) mm to 4 (0–20) mm (p >0.05). In the group 3 calcifications were completely resolved (p <0.05), the volume of fibrosis decreased from 6.8 (3.2–15) mm to 4.5 (1–17) mm (p <0.05). Bacterial growth wasn’t found in 9 patients’ seminal/ prostate fluid, 16 patients had a decrease of the causative agent concentration on 60 day, WBC count normalized in all subjects with CP/chronic pelvic pain syndrome IIIA.Conclusion. ESWT is an effective and non-invasive method of treatment of CP type II, IIIA and IIIB. The proposed treatment to relieve pain syndrome, inflammation, to promote lysis of fibrosis zone and calcinates, improves the draining function of prostate, contributing to accelerated elimination of microflora. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
1 |
| title_short |
Correction of chronic prostatitis by extracorporeal shock wave therapy |
| url |
https://doi.org/10.17650/1726-9784-2022-23-1-53-59 https://doaj.org/article/54213f73dc9548f5bc6c53e0ba250ed6 https://agx.abvpress.ru/jour/article/view/545 https://doaj.org/toc/2070-9781 |
| remote_bool |
true |
| author2 |
А. А. Kostin E. V. Gameeva S. A. Artemenko А. А. Epifanov |
| author2Str |
А. А. Kostin E. V. Gameeva S. A. Artemenko А. А. Epifanov |
| ppnlink |
1760599980 |
| callnumber-subject |
RD - Surgery |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.17650/1726-9784-2022-23-1-53-59 |
| callnumber-a |
RD1-811 |
| up_date |
2024-07-03T22:15:26.034Z |
| _version_ |
1803597828368367616 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ084293039</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410104953.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2022 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17650/1726-9784-2022-23-1-53-59</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ084293039</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ54213f73dc9548f5bc6c53e0ba250ed6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RD1-811</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">M. V. Epifanova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Correction of chronic prostatitis by extracorporeal shock wave therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction. This article presents the results of treatment of patients with chronic prostatitis (CP) type II, IIIA and IIIB by extracorporeal shock wave therapy (ESWT).The study objective was to evaluate the effectiveness of ESWT in the treatment of CP.Materials and methods. The research included 43 patients with CP. The patient’s age was 38.8 (27–65). The mean CP duration was 13.5 (3–24) months. 43 patients were assigned into 3 groups based on transrectal ultrasound (TRUS) examination. Group 1 had fibrotic changes in the prostate (n = 21). Group 2 had prostate calcifications (n = 5). Group 3 had fibrotic changes and calcifications in the prostate (n = 17). Treatment included ESWT (Dornier Aries) twice per week during 6 weeks. Each ESWT-session was comprised 2000–3500 pulses (0.05–0.062 mJ/mm2) and 8–6 Hz of frequency. All men were evaluated on 0 and 60 days of the study using NIH-CPSI (National Institutes Health Chronic Prostatitis Symptom Index), IPSS (International Prostate Symptom Score), TRUS of the prostate, the culture of seminal or prostate fluid, spermogram or prostate fluid analysis, serum prostatic specific antigen for men over 50 years of age.Results. The patients over 50 years-old had total prostatic specific antigen less than 4 ng/ml. Bacterial growth was found in the culture of seminal/prostate fluid of the 26 patients. They were additionally prescribed antibiotics according to antibiogram. All patients got the treatment well. Control study pointed at lower scores of NIH-CPSI – grade decreased from 13.39 (1–34) to 5.54 (0–24) (p &lt;0.05), IPSS decreased from 11.39 (0–34) to 4.39 (0–29) (p &lt;0.05). Prostate volume decreased from 25.18 (12.2–58.8) cm3 to 22.78 (12–56.6) cm3 according to TRUS (p &gt;0.05). In the group 1 in 3 cases local fibrosis were completely resolved, in 18 cases fibrotic changes decreased from 5.3 (0–13) mm to 3.24 (0–8.1) mm (p &lt;0.05). In the second group the number and the size of calcifications decreased from 6.92 (2–21) mm to 4 (0–20) mm (p &gt;0.05). In the group 3 calcifications were completely resolved (p &lt;0.05), the volume of fibrosis decreased from 6.8 (3.2–15) mm to 4.5 (1–17) mm (p &lt;0.05). Bacterial growth wasn’t found in 9 patients’ seminal/ prostate fluid, 16 patients had a decrease of the causative agent concentration on 60 day, WBC count normalized in all subjects with CP/chronic pelvic pain syndrome IIIA.Conclusion. ESWT is an effective and non-invasive method of treatment of CP type II, IIIA and IIIB. The proposed treatment to relieve pain syndrome, inflammation, to promote lysis of fibrosis zone and calcinates, improves the draining function of prostate, contributing to accelerated elimination of microflora.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic prostatitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">extracorporeal shock wave therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic pelvic pain syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Surgery</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">А. А. Kostin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Gameeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. A. Artemenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">А. А. Epifanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Андрология и генитальная хирургия</subfield><subfield code="d">ABV-press, 2015</subfield><subfield code="g">23(2022), 1, Seite 53-59</subfield><subfield code="w">(DE-627)1760599980</subfield><subfield code="x">20709781</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:53-59</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17650/1726-9784-2022-23-1-53-59</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/54213f73dc9548f5bc6c53e0ba250ed6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://agx.abvpress.ru/jour/article/view/545</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2070-9781</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">53-59</subfield></datafield></record></collection>
|
| score |
7.401865 |